Dicot Pharma's LIB-01 Shows Sustained Erectile Dysfunction Treatment Effects in Phase 2a Trial
核心洞察
Dicot Pharma (搜索)'s LIB-01 demonstrated clinically meaningful improvements in erectile function at 4 weeks following a single 3-day oral treatment, with effects sustained through 8 weeks in a phase 2a study of 156 men.
The 50 mg dose showed an 8.5-point improvement from baseline in patients with moderate erectile dysfunction (搜索), with 31% achieving complete response compared to 0% in placebo group.
Based on the positive results showing long-term efficacy, the company has filed a new patent application and plans to initiate a phase 2b study in 2026.
Dicot Pharma (搜索) announced positive topline results from its phase 2a study of LIB-01 for erectile dysfunction (搜索) treatment, demonstrating clinically meaningful improvements in erectile function that persisted for eight weeks following a single three-day oral treatment. The double-blind, placebo-controlled study included 156 men aged 26 to 65 with mild to moderate erectile dysfunction, representing a potential breakthrough in treatment duration for this condition affecting over 500 million men globally.
Study Design and Patient Population
The phase 2a study (NCT06703840) evaluated LIB-01 at three doses - 10 mg, 25 mg, and 50 mg - in patients with International Index of Erectile Function - Erectile Function domain scores (IIEF-EF) of 11-25. Participants were assessed at four and eight weeks following the initial three-day dosing period. The study included pre-specified subgroup analyses based on erectile dysfunction (搜索) severity, with moderate ED defined as baseline IIEF-EF scores of 11-17 and mild to moderate ED as scores of 18-25.
Primary Efficacy Results
At week 4, all LIB-01 treatment groups showed improvement in erectile function, with the 50 mg group demonstrating a 4-point shift from baseline (p=0.0002 vs baseline, p=0.34 vs placebo). This represents a clinically meaningful improvement, exceeding the minimum 2-point shift required for this severity group.
The most pronounced effects were observed in patients with moderate erectile dysfunction (搜索) (IIEF-EF 11-17 at baseline). In this subgroup, the 50 mg dose produced an 8.5-point improvement from baseline (p=0.008 vs baseline, p=0.11 vs placebo), considerably greater than the minimum 5-point shift required for clinical significance. Additionally, 31% of patients in this group achieved complete response (IIEF-EF score >25) compared to 0% in the placebo group (p=0.04 vs placebo). A clear dose-response relationship was evident in this severity group.
Sustained Long-Term Effects
The therapeutic effects of LIB-01 remained sustained over the entire eight-week study period in the two higher dose groups. At week 8, patients with moderate erectile dysfunction (搜索) demonstrated a 7.5-point shift from baseline for the 50 mg group (p=0.03 vs baseline, p=0.06 vs placebo). When the 25 mg and 50 mg groups were pooled, the analysis showed a statistically significant improvement versus placebo (p=0.03) of 6.5 points from baseline.
The pre-defined pooled subgroup of the 25 mg and 50 mg doses at 8 weeks showed statistically significant improvement versus placebo (p=0.03), which will inform the design of the planned phase 2b clinical trial.
Safety Profile
LIB-01 was well tolerated at all dose levels throughout the study. Adverse events were few, mainly mild and transient, occurring during the initial days following LIB-01 administration. The most common adverse event was gastrointestinal upset, which was mild and self-limited.
Clinical Implications and Expert Commentary
The sustained duration of LIB-01's effects represents a potential paradigm shift from current short-acting treatments. Professor Francois Giuliano, Medical Expert in the phase 2a trial and international expert in sexual dysfunctions (搜索), commented: "At a time when the medical community is awaiting therapeutic innovations for erectile dysfunction (搜索), these phase 2a study results are highly encouraging, particularly demonstrating a clear dose-response relationship, a sustained duration of action, and a favorable safety profile."
Dr. Harin Padma-Nathan, international medical expert in erectile dysfunction (搜索) and Principal Investigator for Viagra and Cialis, noted: "Looking at the potential implications and impact of LIB-01, there is now even greater evidence that this molecule may dramatically change first-line therapy with the possibility of infrequent dosing, long duration of efficacy and normalization of erectile function, thus obviating the need for on-demand or daily dosing therapy."
Patent Protection and Development Timeline
Based on the study results demonstrating LIB-01's unique long-term effect, Dicot Pharma (搜索) has submitted a new patent application to strengthen and extend the company's intellectual property protection, which currently lasts until 2042. The priority application was submitted to the Swedish Patent and Registration Office and will proceed to an international Patent Cooperation Treaty application covering 158 countries within 12 months.
CEO Elin Trampe stated: "The results from the phase 2a study show that LIB-01 has a unique long-term effect that persists for eight weeks after only a three-day treatment. This is significantly different from today's short-acting treatments for erectile dysfunction (搜索) and may represent a paradigm shift for the treatment of erection problems."
The company plans to initiate a phase 2b study during 2026, with the sustained efficacy profile pointing toward a potential monthly dosing interval for LIB-01. The results suggest LIB-01 could address the significant unmet medical need in a market valued at USD 8 billion, potentially offering patients and couples a normalized approach to sexual health management.